1. Scrip

Caribou Hit By Familiar Allo CAR-T Durability Problems

Hope For Higher Dose

 
• By Andrew McConaghie

Like some of its allo CAR-T rivals, CB-010’s early promise has fallen away, but Caribou still hopes a higher dose can bring with it real durability of response.

Messe, Vienna.
This year's EHA annual congress returns to an in-person meeting at the Messe in Vienna, Austria. • Source: Shutterstock

Caribou Biosciences looked to have streaked into the lead in the off-the-shelf CAR-T field last month with a 100% complete response rate in its first five evaluable patients, but updated results from the Phase I ANTLER study suggest its candidate, CB-010 suffers from similar durability of response problems to its rivals.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D